Geneos Wealth Management Inc. Has $3.18 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Geneos Wealth Management Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 23.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,294 shares of the biopharmaceutical company's stock after selling 14,494 shares during the period. Geneos Wealth Management Inc.'s holdings in Gilead Sciences were worth $3,176,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of GILD. Manning & Napier Advisors LLC acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $25,328,000. Charles Schwab Investment Management Inc. grew its position in shares of Gilead Sciences by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company's stock worth $589,873,000 after buying an additional 87,482 shares in the last quarter. Eagle Asset Management Inc. increased its stake in shares of Gilead Sciences by 23.6% in the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company's stock worth $25,724,000 after buying an additional 60,697 shares during the last quarter. ARGA Investment Management LP increased its stake in shares of Gilead Sciences by 6.2% in the fourth quarter. ARGA Investment Management LP now owns 635,058 shares of the biopharmaceutical company's stock worth $51,446,000 after buying an additional 37,069 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich raised its holdings in Gilead Sciences by 3.0% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 429,936 shares of the biopharmaceutical company's stock valued at $34,829,000 after acquiring an additional 12,617 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on GILD shares. Morgan Stanley dropped their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an "equal weight" rating for the company in a research report on Friday, April 26th. Evercore ISI raised Gilead Sciences to a "strong-buy" rating in a report on Friday, August 9th. Truist Financial boosted their price target on Gilead Sciences from $82.00 to $83.00 and gave the company a "hold" rating in a report on Thursday, August 15th. Barclays decreased their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an "equal weight" rating for the company in a report on Monday, April 29th. Finally, Robert W. Baird reissued a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a report on Thursday, June 20th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $81.94.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now owns 96,380 shares of the company's stock, valued at approximately $6,614,559.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.82 on Friday, hitting $76.72. The company's stock had a trading volume of 6,844,855 shares, compared to its average volume of 7,242,981. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The stock's 50-day moving average is $71.87 and its two-hundred day moving average is $70.23. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The company has a market capitalization of $95.58 billion, a price-to-earnings ratio of 213.11, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 4.01%. Gilead Sciences's payout ratio is 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.